Soroush Sohrabi: The Hidden Biology of Sclerotherapy and Mechanisms Beyond Endothelial Injury
Soroush Sohrabi, Consultant vascular and ednovascular surgeon at NMC Healthcare, shared a post on LinkedIn:
“Sclerotherapy Reality Check: Blood Inactivates — and the Vein Wall Matters
We often describe sclerotherapy in simple terms: inject the sclerosant, damage the endothelium, the vein closes.
The biology is more complex.
Two important experimental studies help clarify what is really happening:
‘Implication of foam sclerosant inactivation by human whole blood in a laboratory setting’
and
‘Media Damage Following Detergent Sclerotherapy Appears to be Secondary to the Induction of Inflammation and Apoptosis: An Immunohistochemical Study Elucidating Previous Histological Observations.’
These papers demonstrate two critical realities.
- First, blood is not passive. It actively reduces sclerosant activity. Detergent agents rapidly bind to plasma proteins such as albumin, forming inactive complexes. Even small volumes of blood can significantly decrease the active fraction available to act on the vein wall.
- Second, durable vein closure depends on more than superficial endothelial injury. Successful treatment requires deeper medial damage driven by inflammatory and apoptotic pathways. If injury remains too superficial relative to wall thickness, recanalisation becomes more likely.
In simple terms:
- Blood reduces effective drug activity
- The vein wall response determines durability
- Endothelial irritation alone is not enough
Why this matters clinically ?
These mechanistic insights help explain why outcomes vary:
- Larger veins behave differently from smaller veins
- Technique influences drug–wall contact time
- Mixing with blood reduces effective concentration
- Wall thickness influences long-term closure
- Sclerotherapy is not just a chemical injection. It is a biological interaction between sclerosant, blood, and vessel wall.
Understanding that interaction helps us refine technique, counsel patients more accurately, and improve durability of results.
What changes, if any, have these mechanisms prompted in your own approach to sclerotherapy?”

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation